Sign Up to like & get recommendations! 0
Published in 2020 at "Cancer"
DOI: 10.1002/cncr.33163
Abstract: Only 45% of women diagnosed with epithelial ovarian cancer (EOC) will remain alive 5 years after their diagnosis. For several decades, we have seen little progress in terms of overall survival (OS). However, we have… read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.24632
Abstract: Morbidity after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) for colorectal peritoneal carcinomatosis (PC) may negatively affect survival. The objective was to determine the impact of postoperative complications (CX) on survival in patients undergoing CRS + HIPEC… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.25603
Abstract: Background and objectives: Hypertherm intraperitoneal chemotherapy (HIPEC) is increasingly used in the treatment of ovarian, tubal, and primary peritoneal cancer (OC). The aim was to evaluate short‐term morbidity of cytoreductive surgery (CRS) and carboplatin HIPEC. read more here.
Sign Up to like & get recommendations! 0
Published in 2020 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.25939
Abstract: Over the past decade, there has been a considerable increase in the utilization of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of patients with peritoneal metastases. This is due to improved… read more here.
Sign Up to like & get recommendations! 0
Published in 2020 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.26099
Abstract: Variations in care have been demonstrated both within and among institutions in many clinical settings. By standardizing perioperative practices, Enhanced Recovery After Surgery (ERAS) pathways reduce variation in perioperative care. We sought to characterize the… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Journal of surgical oncology"
DOI: 10.1002/jso.26833
Abstract: BACKGROUND Opioid-free anesthesia (OFA) provides analgesia minimizing opioids. OFA has not been evaluated in cytoreductive surgery (CRS) with or without heated intraperitoneal chemotherapy. We aim to evaluate OFA feasibility and effectiveness in CRS. METHODS Retrospective… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.26969
Abstract: Failure to rescue (FTR) is defined as death after a major complication. We evaluated FTR after cytoreductive surgery (CRS) with and without hyperthermic intraperitoneal chemotherapy (HIPEC). read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.27122
Abstract: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS‐HIPEC) is an effective surgical intervention for peritoneal surface malignancy. The effect of myometrium invasion on outcomes is unknown. read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.27125
Abstract: The aim of this study is to evaluate the progression‐free survival (PFS) of recurrent ovarian cancer (ROC) patients treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC). read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.27143
Abstract: We aim to assess the quality and readability of online information available to patients considering cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS‐HIPEC). read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.27171
Abstract: There is a paucity of evidence on the value of intraperitoneal chemotherapy (IPC) following cytoreductive surgery (CRS) for colorectal peritoneal metastasis. This study aimed to evaluate the association between mitomycin C‐IPC and survival outcomes following… read more here.